MedTwenty
Companies

Personalis

This profile is still being built. It is not yet listed in the company index.

MedTwenty Indices and trackers are editorial indicators and business information. They are not investment, financial, legal or medical advice, and not a regulated benchmark.

Summary

Minimal-residual-disease and tumour-informed sequencing company, being acquired by Tempus in a $1.5bn transaction.

Finances

Not published (small company accounts)

Timeline

No verified timeline entries yet.

MedTwenty coverage